Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Summary

This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.

Timeline

Start

2024-09-27

Primary completion

2026-07-30

Completion

2026-07-30

Drugs

Indications